TXG (US)


July 31, 2025

The State of Biopharma, Tools, & Research Spending

By John Leppard

This morning’s Senate Appropriations Committee’s markup of the FY26 Labor / HHS funding bill, which includes a $400M increase (+0.8% YoY) for NIH, should serve as an interim clearing event for life science tools (LST)…

Read More >>

February 8, 2025

Life Science Tools: NIH Indirect Cost Cut Risks

By John Leppard

NIH’s surprise announcement Friday of a 15% cap on indirect costs for both new and existing grants will likely trigger fresh uncertainty for life science tools (LST) manufacturers. While indirect costs are technically distinct from…

Read More >>